2004•Value in HealthOpen access

PCNI6 COMPARATIVE COSTS OF GEMCITABINE/CISPLATIN, PACLITAXEL/CARBOPLATIN AND VINORELBINE/CISPLATIN IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN GERMANY

Helge Bischoff, Michael Hamann, G. Stynes, Sherry Bhalla, D Tilden, Adrian Kielhorn

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Vinorelbine, Gemcitabine, Carboplatin, Cisplatin, Paclitaxel, Oncology, Lung cancer, Medicine

Back to paper search Browse research topics Original source

PCNI6 COMPARATIVE COSTS OF GEMCITABINE/CISPLATIN, PACLITAXEL/CARBOPLATIN AND VINORELBINE/CISPLATIN IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN GERMANY — Research Paper | ScholarLens